oral semaglutide 50 mg oasis 1 nejm 2023 obesity trial Higher-dose oral semaglutide may be beneficial option for type 2 diabetes, obesity The Science | ReMedical

NaCl 10ml

Common side effectsnausea, constipation, loss of appetitetypically decrease over days to weeks as your body adjusts

The FDA's 2023 guidance clarified that traditional compounding pharmacies can continue dispensing semaglutide for individual patients

Engaging with a multidisciplinary team including dietitians, specialist nurses, and where appropriate, psychologists is consistent with NICE recommendations for comprehensive obesity management and will help ensure the safest possible experience with this emerging treatment

Why most clinics haven't added Semaglutide yet Overwhelmed by where to begin No structured workflow for patient onboarding Unsure how to attract and convert patient Struggling to keep patients on their treatment plan No documentation or clinical forms in place THE SOLUTION A step-by-step approach to offering Semaglutide in your clinic We cut straight to the chase equipping you with everything you need to welcome your first Semaglutide patient with confidence